Nasdaq
$1.24▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.4MShares out 7.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 9.28After-hours26.09.29 06:13DEF 14AOther#●●●
BIOVIE INC.Bullish
BioVie Inc. will hold its 2026 Annual Meeting of Stockholders on November 10, 2026, to vote on the election of six directors, the ratification of its auditor, and an amendment to the 2019 Omnibus Equity Incentive Plan. The proposal seeks to increase the number of shares available for issuance under the plan from 399,509 to 3,100,000, which may lead to significant dilution for existing shareholders.…more
$1.24+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.3After-hours26.09.04 05:03SCHEDULE 13GOwnership
BIOVIE INC.
Jane Street Group, LLC has filed a Schedule 13G, reporting a beneficial ownership of more than 5% of BioVie Inc. common stock. This filing officially confirms the investor's significant stake in the company.…more
$1.24+0.00%vs prev closeView filingShare - 8.29Closed26.08.29 10:014Ownership
BIOVIE INC.
BioVie Inc. insider Joseph M. Palumbo filed an SEC Form 4 on August 28, 2026, reporting a change in his beneficial ownership of company securities. The filing provides the official record of these equity transactions.…more
$1.24+0.00%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:08#●●●#●●●#●●●
BioVie Presents Phase 2 Data for Long COVID Drug Bezisterim
BioVie announced the presentation of Phase 2 study results for its drug candidate bezisterim in Long COVID patients at the American Neurological Association annual meeting. The study abstract was published in the Annals of Neurology, though specific efficacy metrics were not detailed.…more
$1.24+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 21:07
●●●●●●●● ●●●●● ●●●●●●
BioVie will present Phase 2 data for its drug candidate Bezisterim in long COVID and Parkinson's at a neurology conference on October 18-19. As this is a scheduled data presentation, the impact remains neutral until the clinical outcomes are verified.…more
$1.24+0.00%vs prev closeShareBenzinga - 9.15Regular26.09.16 01:21
●●●●●●●● ●●●●● ●●●●●●
BioVie shares fell as the company's Phase 2 trial for its Long COVID drug failed to reach statistical significance across the overall study population. While specific subgroups showed improvement, investors reacted negatively to the need for further prospective studies to confirm efficacy.…more
$1.24+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report